UB Paderborn / Katalog / Suche / in CDI

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413

1997

Volltextzugriff (PDF)

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

British journal of cancer, 2014-02, Vol.110 (3), p.602-608

2014

Volltextzugriff (PDF)

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

The lancet oncology, 2013, Vol.14 (1), p.72-80

2013

Volltextzugriff (PDF)

Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229

Journal of clinical oncology, 1996-03, Vol.14 (3), p.974-977

1996

Volltextzugriff (PDF)

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Journal of clinical oncology, 2023-08, Vol.41 (23), p.3881-3890

2023

Volltextzugriff (PDF)

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

The lancet oncology, 2015-09, Vol.16 (9), p.1071-1078

2015

Volltextzugriff (PDF)

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

The lancet oncology, 2015-09, Vol.16 (9), p.1079-1089

2015

Volltextzugriff (PDF)

Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma

Investigational new drugs, 1990-08, Vol.8 (3), p.317-319

1990

Volltextzugriff (PDF)

North American Conference on Cancer in Hispanics

JNCI : Journal of the National Cancer Institute, 1992-04, Vol.84 (8), p.644-644

Modiano, M R

1992

Volltextzugriff (PDF)

Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1452-1458

2003

Volltextzugriff (PDF)

Ocular Toxic Effects of Fenretinide

JNCI : Journal of the National Cancer Institute, 1990-06, Vol.82 (12), p.1063-1063

1990

Volltextzugriff (PDF)

CT findings after hepatic chemoembolization

Journal of computer assisted tomography, 1992-11, Vol.16 (6), p.916-920

1992

Volltextzugriff (PDF)

Abstract P6-12-15: Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-12-15

2017

Volltextzugriff (PDF)

An educational program to increase cervical and breast cancer screening in Hispanic women: a Southwest Oncology Group study

Cancer nursing, 2005-01, Vol.28 (1), p.47

2005

Volltextzugriff (PDF)

Predictors of cervical cancer screening in Mexican American women of reproductive age

Journal of health care for the poor and underserved, 1998-02, Vol.9 (1), p.76-95

1998

Volltextzugriff (PDF)

A phase I study of TPI 287, a novel taxane, administered every 21 days in patients (pts) with advanced cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.13510-13510

2008

Volltextzugriff (PDF)

Cancer in Hispanics: issues of concern

Journal of the National Cancer Institute. Monographs, 1995 (18), p.35-39

1995

Volltextzugriff (PDF)

A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4619-4619

2008

Volltextzugriff (PDF)

A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.2536-2536

2008

Volltextzugriff (PDF)

Breast and Cervical Cancer in Hispanic Women

Medical anthropology quarterly, 1995-03, Vol.9 (1), p.75-77

MODIANO, MANUEL R.

1995

Volltextzugriff (PDF)

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy

American journal of clinical oncology, 1996-12, Vol.19 (6), p.619-623

1996

Volltextzugriff (PDF)

Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide

Clinical cancer research, 2003-07, Vol.9 (7), p.2400-2405

2003

Volltextzugriff (PDF)

Randomized, double blind, dose‐response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy

Cancer, 1997-03, Vol.79 (6), p.1216-1224

1997

Volltextzugriff (PDF)

A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy

Seminars in oncology, 1992-04, Vol.19 (2 Suppl 3), p.185

1992

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma

North American Conference on Cancer in Hispanics

Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant

Ocular Toxic Effects of Fenretinide

CT findings after hepatic chemoembolization

Abstract P6-12-15: Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

An educational program to increase cervical and breast cancer screening in Hispanic women: a Southwest Oncology Group study

Predictors of cervical cancer screening in Mexican American women of reproductive age

A phase I study of TPI 287, a novel taxane, administered every 21 days in patients (pts) with advanced cancer

Cancer in Hispanics: issues of concern

A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity

A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer

Breast and Cervical Cancer in Hispanic Women

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy

Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide

Randomized, double blind, dose‐response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy

A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy

Suchergebnisse filtern